Trombocytopenia related to colchicine: Report of two cases
| dc.contributor.author | Karakurt, Neslihan | |
| dc.contributor.author | Candir, Mehmet Onur | |
| dc.contributor.author | Kosan Culha, Vildan | |
| dc.contributor.author | Yarali, Nese | |
| dc.contributor.author | Cakar, Nilgun | |
| dc.contributor.author | Ozbek, Namik | |
| dc.date.accessioned | 2022-02-16T13:08:21Z | |
| dc.date.available | 2022-02-16T13:08:21Z | |
| dc.date.issued | 2017 | |
| dc.department | İnönü Üniversitesi | en_US |
| dc.description.abstract | Familial Mediterranean fever (FMF) is the most frequent autoinflammatory disease which can be well controlled with lifelong use of colchicine. Daily colchicine use has been shown to reduce the frequency, severity, and duration of attacks. Colchicine also has been found to be effective in decreasing the prevalence of amyloidosis. Therapeutic oral dose of colchicine (0.5-2.0 mg/ day) may cause cramping, abdominal pain, hyperperistalsis, diarrhea and vomiting. Besides, colchicine may rarely cause bone marrow failure, agranulocytosis and/ or thrombocytopenia as well. Here in we report two pediatric cases of FMF who developed trombocytopenia after colchicine medication and call attention to colchicine related trombocytopenia. | en_US |
| dc.identifier.citation | Karakurt, N., Onur Candir, M., Kosan Culha, V., Yarali, N., Cakar, N., & Ozbek, N. (2021). Trombocytopenia related to colchicine: Report of two cases . Annals of Medical Research | en_US |
| dc.identifier.doi | 10.5455/jtomc.2016.09.103 | en_US |
| dc.identifier.uri | https://hdl.handle.net/11616/47314 | |
| dc.language.iso | en | en_US |
| dc.relation.ispartof | Annals of Medical Research | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Trombocytopenia related to colchicine: Report of two cases | en_US |
| dc.type | Article | en_US |
